Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

Price Sensitive Information

30 Apr 2009 12:55

RNS Number : 4931R
Beximco Pharmaceuticals Ltd
30 April 2009
 



BEXIMCO PHARMACEUTICALS LTD.

30th April, 2009

PRICE SENSITIVE INFORMATION

Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) today announces information for Shareholders of the Company that the Board of Directors in their meeting held on 30th April, 2009 at 5.00 p.m. has decided the following: 

1. Revaluation of Assets of the Company: 

Accepted an independent report on the valuation of

Lands, Buildings, Plant and Machinery as of 31 December, 2008 issued by M/S S F Ahmed & Co. Chartered Accountants and Valuer showing an aggregate depreciated current cost of Tk 5,485,286,356 resulting in a revaluations surplus aggregating Tk 1,711,174,747

 

2. Date & Time of 33rd AGM of the: 

Company for the year 2008

 

16th June, 2009 at 9.30 a.m

3. Proposed Dividend:

10% Cash and 20% Stock dividend 

for the year ended 31 December 2008

 

4. Record date:

25th May, 2009.

 

5. Venue of AGM:

1 Shahbag C/A, DhakaBangladesh

 

For further enquiries please contact:

 

Beximco Pharma

Nazmul Hassan, CEO

MD. ASAD ULLAH, FCS, Company Secretary

Tel: +880 2 861 9151, ext.2080

 

Libertas Capital

Jakob Kinde / Anthony Rowland

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in DhakaBangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri LankaNepalBhutanVietnamCambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFBLFXKZBEBBX
Date   Source Headline
31st Mar 20067:01 amRNSProduct Launch
16th Dec 20057:01 amRNSTrading Statement
21st Oct 20057:00 amRNSAdmission to AIM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.